235 related articles for article (PubMed ID: 12889739)
1. Mechanistic models for myelosuppression.
Friberg LE; Karlsson MO
Invest New Drugs; 2003 May; 21(2):183-94. PubMed ID: 12889739
[TBL] [Abstract][Full Text] [Related]
2. Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression.
Hansson EK; Wallin JE; Lindman H; Sandström M; Karlsson MO; Friberg LE
Cancer Chemother Pharmacol; 2010 Apr; 65(5):839-48. PubMed ID: 19680655
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs.
Kloft C; Wallin J; Henningsson A; Chatelut E; Karlsson MO
Clin Cancer Res; 2006 Sep; 12(18):5481-90. PubMed ID: 17000683
[TBL] [Abstract][Full Text] [Related]
4. The shape of the myelosuppression time profile is related to the probability of developing neutropenic fever in patients with docetaxel-induced grade IV neutropenia.
Hansson EK; Friberg LE
Cancer Chemother Pharmacol; 2012 Apr; 69(4):881-90. PubMed ID: 22057837
[TBL] [Abstract][Full Text] [Related]
5. Model-based neutrophil-guided dose adaptation in chemotherapy: evaluation of predicted outcome with different types and amounts of information.
Wallin JE; Friberg LE; Karlsson MO
Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):234-42. PubMed ID: 20050841
[TBL] [Abstract][Full Text] [Related]
6. Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies.
Soto E; Keizer RJ; Trocóniz IF; Huitema AD; Beijnen JH; Schellens JH; Wanders J; Cendrós JM; Obach R; Peraire C; Friberg LE; Karlsson MO
Invest New Drugs; 2011 Oct; 29(5):984-95. PubMed ID: 20449627
[TBL] [Abstract][Full Text] [Related]
7. Neutrophil dynamics during concurrent chemotherapy and G-CSF administration: Mathematical modelling guides dose optimisation to minimise neutropenia.
Craig M; Humphries AR; Nekka F; Bélair J; Li J; Mackey MC
J Theor Biol; 2015 Nov; 385():77-89. PubMed ID: 26343861
[TBL] [Abstract][Full Text] [Related]
8. Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia.
Hing J; Perez-Ruixo JJ; Stuyckens K; Soto-Matos A; Lopez-Lazaro L; Zannikos P
Clin Pharmacol Ther; 2008 Jan; 83(1):130-43. PubMed ID: 17597713
[TBL] [Abstract][Full Text] [Related]
9. Optimization of drug regimen in chemotherapy based on semi-mechanistic model for myelosuppression.
Zhu J; Liu R; Jiang Z; Wang P; Yao Y; Shen Z
J Biomed Inform; 2015 Oct; 57():20-7. PubMed ID: 26146158
[TBL] [Abstract][Full Text] [Related]
10. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs.
Friberg LE; Henningsson A; Maas H; Nguyen L; Karlsson MO
J Clin Oncol; 2002 Dec; 20(24):4713-21. PubMed ID: 12488418
[TBL] [Abstract][Full Text] [Related]
11. Quantitative Systems Pharmacology Modeling of Avadomide-Induced Neutropenia Enables Virtual Clinical Dose and Schedule Finding Studies.
Abbiati RA; Pourdehnad M; Carrancio S; Pierce DW; Kasibhatla S; McConnell M; Trotter MWB; Loos R; Santini CC; Ratushny AV
AAPS J; 2021 Aug; 23(5):103. PubMed ID: 34453265
[TBL] [Abstract][Full Text] [Related]
12. Models of schedule dependent haematological toxicity of 2'-deoxy-2'-methylidenecytidine (DMDC).
Friberg LE; Brindley CJ; Karlsson MO; Devlin AJ
Eur J Clin Pharmacol; 2000 Nov; 56(8):567-74. PubMed ID: 11151746
[TBL] [Abstract][Full Text] [Related]
13. Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation Approach.
Sun W; O'Dwyer PJ; Finn RS; Ruiz-Garcia A; Shapiro GI; Schwartz GK; DeMichele A; Wang D
J Clin Pharmacol; 2017 Sep; 57(9):1159-1173. PubMed ID: 28419480
[TBL] [Abstract][Full Text] [Related]
14. Topotecan dosing guidelines in ovarian cancer: reduction and management of hematologic toxicity.
Armstrong DK
Oncologist; 2004; 9(1):33-42. PubMed ID: 14755013
[TBL] [Abstract][Full Text] [Related]
15. Covariate-based dose individualization of the cytotoxic drug indisulam to reduce the risk of severe myelosuppression.
Zandvliet AS; Schellens JH; Copalu W; Beijnen JH; Huitema AD
J Pharmacokinet Pharmacodyn; 2009 Feb; 36(1):39-62. PubMed ID: 19199010
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy-induced myelosuppression by vinorelbine: a comparison between different dose schedules by simulation.
Urso R; Nencini C; Giorgi G; Fiaschi AI
Eur Rev Med Pharmacol Sci; 2007; 11(6):413-7. PubMed ID: 18306910
[TBL] [Abstract][Full Text] [Related]
17. Optimization of clinical dosing schedule to manage neutropenia: learnings from semi-mechanistic modeling simulation approach.
Guo Y; Haddish-Berhane N; Xie H; Ouellet D
J Pharmacokinet Pharmacodyn; 2020 Feb; 47(1):47-58. PubMed ID: 31853740
[TBL] [Abstract][Full Text] [Related]
18. A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression model.
Quartino AL; Friberg LE; Karlsson MO
Invest New Drugs; 2012 Apr; 30(2):833-45. PubMed ID: 21153753
[TBL] [Abstract][Full Text] [Related]
19. Mechanism-based models for topotecan-induced neutropenia.
Léger F; Loos WJ; Bugat R; Mathijssen RH; Goffinet M; Verweij J; Sparreboom A; Chatelut E
Clin Pharmacol Ther; 2004 Dec; 76(6):567-78. PubMed ID: 15592328
[TBL] [Abstract][Full Text] [Related]
20. Model-based prediction of myelosuppression and recovery based on frequent neutrophil monitoring.
Netterberg I; Nielsen EI; Friberg LE; Karlsson MO
Cancer Chemother Pharmacol; 2017 Aug; 80(2):343-353. PubMed ID: 28656382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
